Upstream Bio Appoints Allison Ambrose as General Counsel
Upstream Bio (Nasdaq: UPB) has appointed Allison Ambrose as General Counsel, bringing over 15 years of experience in legal leadership. Ambrose, who previously served as General Counsel at Skyhawk Therapeutics and held leadership roles at Ginkgo Bioworks and Orchard Therapeutics, will oversee all legal functions and join the executive team.
The appointment comes at a important time for Upstream Bio, a clinical-stage company focused on developing treatments for inflammatory diseases, particularly verekitug for severe respiratory disorders. Ambrose's expertise spans corporate governance, securities law, compliance, and capital markets transactions, which will be valuable as the company advances its development programs as a newly public entity.
Upstream Bio (Nasdaq: UPB) ha nominato Allison Ambrose come Direttore Legale, portando con sé oltre 15 anni di esperienza nella leadership legale. Ambrose, che in precedenza ha ricoperto il ruolo di Direttore Legale presso Skyhawk Therapeutics e ha avuto ruoli di leadership in Ginkgo Bioworks e Orchard Therapeutics, supervisionerà tutte le funzioni legali e si unirà al team esecutivo.
La nomina arriva in un momento importante per Upstream Bio, un'azienda in fase clinica focalizzata nello sviluppo di trattamenti per malattie infiammatorie, in particolare verekitug per disturbi respiratori gravi. L'expertise di Ambrose comprende la governance aziendale, la normativa sui valori mobiliari, la conformità e le transazioni nei mercati dei capitali, che sarà preziosa mentre l'azienda avanza nei suoi programmi di sviluppo come nuovo ente pubblico.
Upstream Bio (Nasdaq: UPB) ha nombrado a Allison Ambrose como Consejera General, aportando más de 15 años de experiencia en liderazgo legal. Ambrose, quien anteriormente se desempeñó como Consejera General en Skyhawk Therapeutics y ocupó cargos de liderazgo en Ginkgo Bioworks y Orchard Therapeutics, supervisará todas las funciones legales y se unirá al equipo ejecutivo.
La designación llega en un momento importante para Upstream Bio, una empresa en etapa clínica centrada en el desarrollo de tratamientos para enfermedades inflamatorias, particularmente verekitug para trastornos respiratorios severos. La experiencia de Ambrose abarca la gobernanza corporativa, la legislación de valores, el cumplimiento y las transacciones en mercados de capitales, lo que será valioso a medida que la empresa avance en sus programas de desarrollo como una nueva entidad pública.
Upstream Bio (Nasdaq: UPB)는 Allison Ambrose를 법률 고문으로 임명했습니다. 그녀는 15년 이상의 법률 리더십 경험을 가지고 있습니다. Ambrose는 이전에 Skyhawk Therapeutics에서 법률 고문으로 근무했으며 Ginkgo Bioworks와 Orchard Therapeutics에서 리더십 역할을 수행했습니다. 그녀는 모든 법률 기능을 감독하고 경영진 팀에 합류할 것입니다.
이번 임명은 염증성 질환을 위한 치료제 개발에 주력하는 임상 단계 회사인 Upstream Bio에 중요한 시기에 이루어졌습니다. 특히 verekitug는 심각한 호흡기 질환을 위한 약물입니다. Ambrose의 전문 분야는 기업 거버넌스, 증권법, 규정 준수 및 자본 시장 거래로, 새로운 상장 기업으로서 회사가 발전하는 과정에서 큰 도움이 될 것입니다.
Upstream Bio (Nasdaq: UPB) a nommé Allison Ambrose en tant que Conseillère Juridique, apportant plus de 15 ans d'expérience dans le leadership juridique. Ambrose, qui a précédemment occupé le poste de Conseillère Juridique chez Skyhawk Therapeutics et a occupé des postes de direction chez Ginkgo Bioworks et Orchard Therapeutics, supervisera toutes les fonctions juridiques et rejoindra l'équipe exécutive.
Cette nomination intervient à un moment important pour Upstream Bio, une entreprise en phase clinique axée sur le développement de traitements pour les maladies inflammatoires, en particulier verekitug pour les troubles respiratoires sévères. L'expertise d'Ambrose couvre la gouvernance d'entreprise, le droit des valeurs mobilières, la conformité et les transactions sur les marchés des capitaux, ce qui sera précieux alors que l'entreprise fait avancer ses programmes de développement en tant que nouvelle entité publique.
Upstream Bio (Nasdaq: UPB) hat Allison Ambrose zur General Counsel ernannt und bringt über 15 Jahre Erfahrung in der rechtlichen Führung mit. Ambrose, die zuvor als General Counsel bei Skyhawk Therapeutics tätig war und Führungspositionen bei Ginkgo Bioworks und Orchard Therapeutics innehatte, wird alle rechtlichen Funktionen überwachen und dem Führungsteam beitreten.
Die Ernennung erfolgt zu einem wichtigen Zeitpunkt für Upstream Bio, ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für entzündliche Erkrankungen konzentriert, insbesondere verekitug für schwere Atemwegserkrankungen. Ambroses Fachwissen umfasst Unternehmensführung, Wertpapierrecht, Compliance und Kapitalmarkttransaktionen, was von Bedeutung sein wird, während das Unternehmen seine Entwicklungsprogramme als neu öffentliches Unternehmen vorantreibt.
- Strengthened executive team with experienced legal counsel having 15+ years of expertise
- Addition of leadership with public company and biotech industry experience
- Enhanced capability in corporate governance and securities compliance as a newly public company
- None.
WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream’s legal function and join the Company’s executive leadership team.
“I am thrilled to welcome Allison to the Upstream Bio team,” said Rand Sutherland, M.D., Upstream Bio’s Chief Executive Officer. “Allison’s extensive experience in the biotech industry has come from helping numerous growth-stage companies work towards their business goals. Her legal and strategic counsel will be critically important as we optimize the Company to focus on our key objective of successfully developing verekitug across multiple indications.”
“I am excited to join Upstream at this pivotal time in the Company’s development, particularly as a newly public company,” added Ms. Ambrose. “Upstream is well positioned to address unmet needs in severe respiratory disorders with verekitug. I look forward to working with the team to continue to advance verekitug as we seek to make an impact for patients with serious inflammatory diseases.”
Ms. Ambrose joins Upstream from Skyhawk Therapeutics where she served as General Counsel with responsibility for the legal and compliance functions. Previously, she held legal leadership roles of increasing responsibility at Ginkgo Bioworks, a publicly-traded biotechnology company, and Orchard Therapeutics, a then-publicly traded biotechnology company that was acquired in January 2024. In each of these roles, Allison provided legal direction in areas including corporate governance, securities compliance, capital markets and strategic business transactions, and other corporate matters. Prior to her in-house legal roles, Allison was a corporate associate at Ropes & Gray LLP where she advised public and private companies primarily in the life sciences industry. Allison holds a J.D. from Georgetown University Law Center and a B.A. from the University of Tennessee.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as "aims," "anticipates," "believes," “continue,” "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," “predict,” “project,” "seeks," “should,” “target,” "will" and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding: management’s ability to optimize the Company to achieve its business objectives; the development of verekitug across multiple indications; and the Company’s ability to advance verekitug to address unmet needs in severe respiratory disorders. Any forward-looking statements in this press release are based on Upstream’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in Upstream’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream’s ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; Upstream’s ability to fund its development activities and achieve development goals; Upstream’s dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream’s ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream’s financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream’s competitors and industry; and other risks and uncertainties described in Upstream’s current and future filings with the SEC, including those described from time to time under the caption “Risk Factors.” Upstream explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
FAQ
Who is the new General Counsel at Upstream Bio (UPB) and what is their background?
What is Upstream Bio's (UPB) main focus in drug development?
What are the key responsibilities of the new General Counsel at Upstream Bio (UPB)?
How will the new General Counsel appointment impact Upstream Bio's (UPB) development strategy?
